Overview

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.
Phase:
Phase 2
Details
Lead Sponsor:
Therapeutics, Inc.